Brainstorm Cell Therapeutics CEO and leadership

Chaim Lebovits has been at the forefront of mining and natural resource management in African regions for over a decade. He has spent years leading the exploration and development of resources in the Democratic Republic of Congo on behalf of world-leading firms. In this capacity, he has negotiated numerous, highly-successful deals on behalf of both African governments and global mining concerns. As an internationally known and respected business mogul and corporate manager, Lebovits has developed excellent personal relations with numerous African leaders, and has promoted the interests of their countries in the economic and political capitals of the world, both in official and unofficial capacities. Lebovits leads ACC HOLDINGS INTERNATIONAL and its many subsidiaries with his extensive experience and passion for the mining, oil, and energy industry, with intentions of taking ACC to a level of excellence and leadership in the resource mining sector. His commitment to the people that work with him, and to health, environmental and social issues, is evident in his projects in Africa. Lebovits into BrainStorm through ACCBT (ACC BioTech). ACCBT is one of ACC's subsidiaries that is totally focused on biotechnology. Originally from New York, Lebovits moved to Israel and now resides in Jerusalem. Lebovits has worked in senior positions for the worldwide Chabad Lubavitch organization and in the mining business, and launched his own private companies in 2005. Lebovits now splits his time between North America, Europe, Africa, and the Middle East.

I've earned my PhD in Molecular Biology at Weizmann Institute of Science and did my post-doctoral studies at the Albert Einstein College of Medicine in N.Y.

Head the Neurology Laboratory at Tel Aviv University in the Department of Human Genetics and Biochemistry.

I enjoy internationally recognized reputation in neuroscience research.

I've published over 150 original scientific papers on neurodegenerative diseases and I'm co-inventor in over a dozen patents.

Co-founder of several biotechnology companies developing gene and cell therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics, showed efficacy in ALS patients in a Phase II clinical trial.

Uri Yablonka is a Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS and is based in United States.

Pharmaceutical C executive in charge of corporate development, strategy and commercial activities.VP @ Life Biosciences - Start-up in aging. Previously CEO /General Manager at Biogen France. Self-starter, hands on leader with strategic mindset and very strong work ethic values. Drives results, strong communication and managerial skills. Scientific orientation to serve patient.Has created a global non for profit organization. Current Chair and President of the Academy for Health & Lifespan Research, a non-profit aimed at accelerating breakthroughs in longevity. Bringing together worldwide scientists to drive more understanding and more investment in the field for aging.

I've earned my PhD in Molecular Biology at Weizmann Institute of Science and did my post-doctoral studies at the Albert Einstein College of Medicine in N.Y.

Head the Neurology Laboratory at Tel Aviv University in the Department of Human Genetics and Biochemistry.

I enjoy internationally recognized reputation in neuroscience research.

I've published over 150 original scientific papers on neurodegenerative diseases and I'm co-inventor in over a dozen patents.

Co-founder of several biotechnology companies developing gene and cell therapies for neurological disorders. One of them, Brainstorm Cell Therapeutics, showed efficacy in ALS patients in a Phase II clinical trial.

Uri Yablonka is a Chief Operating Officer at BRAINSTORM CELL THERAPEUTICS and is based in United States.